Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Placebo Condition

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43857   clinical trials with a EudraCT protocol, of which   7284   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,565 result(s) found for: Placebo Condition. Displaying page 41 of 79.
    «« First « Previous 37  38  39  40  41  42  43  44  45  Next» Last»»
    EudraCT Number: 2020-003476-41 Sponsor Protocol Number: ANB019-206 Start Date*: 2021-07-17
    Sponsor Name:AnaptysBio Inc.
    Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ANB019 in the Treatment of Subjects with Ichthyosis
    Medical condition: Ichthyosis
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004858 10037159 Psoriasis pustular LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-000520-19 Sponsor Protocol Number: BAY2586116/20849 Start Date*: 2021-02-10
    Sponsor Name:Bayer AG
    Full Title: Proof-of-concept, multi-center, randomized, double-blind, placebo-controlled, two-way crossover study to investigate the effect strength of BAY 2586116 on the apnea-hypopnea-index after repetitive ...
    Medical condition: Sleep Apnea, Obstructive
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10055577 Obstructive sleep apnea syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-000351-95 Sponsor Protocol Number: R727-CL-1628 Start Date*: 2017-07-18
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ALIROCUMAB IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
    Medical condition: HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10057080 Homozygous familial hypercholesterolemia LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed) AT (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-002824-17 Sponsor Protocol Number: ACCOST-HH Start Date*: 2019-02-28
    Sponsor Name:University Medical Centre Hamburg-Eppendorf
    Full Title: Placebo-controlled, double-blind, randomized trial to assess the efficacy and safety of Adrecizumab in subjects with cardiogenic shock
    Medical condition: Cardiogenic shock
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10007625 Cardiogenic shock PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2022-003221-22 Sponsor Protocol Number: TAK-555-3010 Start Date*: 2024-01-15
    Sponsor Name:Takeda Development Center Americas, Inc.
    Full Title: Phase 3, Multicenter, Randomized Study With 2 Different Doses of Prucalopride Administered to Male and Female Pediatric Subjects Aged 6 Months to 17 Years With Functional Constipation, Consisting o...
    Medical condition: Constipation
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2017-004149-26 Sponsor Protocol Number: METRIS-HF(EMPA) Start Date*: 2018-06-26
    Sponsor Name:Charité Universitätsmedizin Berlin
    Full Title: Effect of Metformin and Empagliflozin in insulin resistant patients with heart failure with reduced ejection fraction
    Medical condition: Heart Failure with reduced ejection fraction (HFrEF and HFmrEF)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-005130-22 Sponsor Protocol Number: FFIS/2015/01/ST Start Date*: 2016-08-03
    Sponsor Name:Fundación para la Formación e Investigación Sanitaria (FFIS)
    Full Title: Randomised Controlled Trial with Pravastatin versus Placebo for Prevention of Pre-eclampsia
    Medical condition: Pre-eclampsia
    Disease: Version SOC Term Classification Code Term Level
    19.0 10036585 - Pregnancy, puerperium and perinatal conditions 10036485 Pre-eclampsia PT
    Population Age: Adults Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Prematurely Ended) BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-001214-16 Sponsor Protocol Number: BXL628 02 16 Start Date*: 2007-07-03
    Sponsor Name:BIOXELL SPA
    Full Title: A randomized, double-blind, placebo-controlled, parallel-group, multi-centre, Phase IIb, study to determine the effect of BXL628 in women with detrusor overactivity
    Medical condition: Overactive Bladder (OAB)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020853 Hypertonic bladder LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed) NL (Completed) GB (Completed) EE (Completed) LT (Completed) LV (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-003609-80 Sponsor Protocol Number: ECASS-4:ExTEND Start Date*: 2014-01-23
    Sponsor Name:Ruprecht-Karls-University Heidelberg, Medical Faculty
    Full Title: European Cooperative Acute Stroke Study-4: Extending the time for thrombolysis in emergency neurological deficits.
    Medical condition: Acute Ischemic Stroke
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) AT (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) CZ (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-001074-27 Sponsor Protocol Number: TG-M-004 Start Date*: 2005-08-02
    Sponsor Name:ThromboGenics Ltd.
    Full Title: A Multi-Centre, Double-Blind, Placebo-Controlled, Ascending-Dose, Clinical Trial of Intra-venous Microplasmin Administration in Patients with Acute Ischemic Stroke
    Medical condition: Acute Ischemic Stroke
    Disease: Version SOC Term Classification Code Term Level
    8.1 10055221 Ischemic stroke LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) AT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-001936-59 Sponsor Protocol Number: 191622-077 Start Date*: 2005-07-30
    Sponsor Name:ALLERGAN LTD
    Full Title: A multicenter, double-blind, randomized, placebo-controlled, parallel-group, dose-response study of the safety and efficacy of a single treatment of BOTOX® (botulinum toxin type A) purified neuroto...
    Medical condition: Idiopathic overactive bladder (symptoms of frequency and urgency) with urinary incontinence.
    Disease: Version SOC Term Classification Code Term Level
    7.1 10059617 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2005-002568-27 Sponsor Protocol Number: PM-C-0172 Start Date*: 2006-05-08
    Sponsor Name:Sanofi-Synthelabo Groupe
    Full Title: A randomized, double blind, two-arm placebo controlled, 12-Month study of the effects of rimonabant 20mg once daily on the amount and the activity of visceral fat in abdominally obese patients with...
    Medical condition: Abdominally obese patients with metabolic syndrome
    Disease: Version SOC Term Classification Code Term Level
    8.0 10029883 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) DK (Completed) SE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-006854-24 Sponsor Protocol Number: ALA-AK-CT002 Start Date*: 2008-04-17
    Sponsor Name:Biofrontera Bioscience GmbH
    Full Title: A randomized, observer blind, multinational phase III study to evaluate the safety and efficacy of a nanoemulsion gel formulation BF-200 ALA, in comparison with Metvix® and placebo, for the treatme...
    Medical condition: Actinic keratosis (AK)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000614 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) AT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-005008-41 Sponsor Protocol Number: 2007033 Start Date*: Information not available in EudraCT
    Sponsor Name:Procter & Gamble Pharmaceuticals
    Full Title: A Phase II, Randomized, Adaptive Design, Multicenter, Parallel Group, Placebo-controlled, 58-day, Dose-ranging Study of ATI-7505 in Patients with Postprandial Distress Syndrome
    Medical condition: Postprandial Distress Syndrome
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064536 Functional dyspepsia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) BE (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-003029-16 Sponsor Protocol Number: GO29505 Start Date*: 2014-12-01
    Sponsor Name:Genentech, Inc.
    Full Title: A phase II randomized, double-blind study of ipatasertib (GDC-0068), an inhibitor to Akt in combination with paclitaxel as neoadjuvant treatment for patients with early stage triple negative breast...
    Medical condition: Early stage triple negative breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2014-003326-41 Sponsor Protocol Number: 200719 Start Date*: 2016-01-13
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: Randomized, Double-Blind, Multicenter, Phase III Study Comparing the Efficacy and Safety of Retosiban Versus Placebo for Women in Spontaneous Preterm Labor
    Medical condition: Preterm Labour
    Disease: Version SOC Term Classification Code Term Level
    19.1 10036585 - Pregnancy, puerperium and perinatal conditions 10036600 Premature labour PT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: GB (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-002465-35 Sponsor Protocol Number: B3461028 Start Date*: 2014-04-07
    Sponsor Name:FoldRx Pharmaceuticals, a Pfizer Company
    Full Title: A multicentre, international, phase 3, double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of daily oral dosing of tafamidis meglumine (PF-06291826)...
    Medical condition: Transthyretin amyloid cardiomyopathy (TTR-CM)
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004849 10002020 Amyloid cardiomyopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IT (Completed) ES (Completed) DE (Completed) SE (Completed) CZ (Completed) NL (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2020-000405-83 Sponsor Protocol Number: VP-VYV-683-3201 Start Date*: 2021-04-09
    Sponsor Name:Vanda Pharmaceuticals Inc.
    Full Title: A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of iloperidone for 4 weeks in the treatment of patients with acute manic episodes associated wi...
    Medical condition: Acute manic episodes associated with Bipolar I Disorder
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10004939 Bipolar I disorder PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-005068-97 Sponsor Protocol Number: AC-052-414 Start Date*: Information not available in EudraCT
    Sponsor Name:Actelion Pharmaceuticals Ltd.
    Full Title: Effects of combination of bosentan and sildenafil versus sildenafil monotherapy on morbidity and mortality in symptomatic patients with pulmonary arterial hypertension – A multicenter, double - bli...
    Medical condition: Patients to be included must have PAH belonging to WHO Group I, in agreement with the approved indications for sildenafil in PAH by the US FDA: a.Idiopathic (IPAH) b.Familial (FPAH) c.Associated w...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064908 Associated with (APAH) LLT
    9.1 10064909 Idiopathic (IPAH) LLT
    9.1 10064910 Familial (FPAH) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) DK (Completed) GB (Completed) ES (Completed) PT (Completed) GR (Completed) BE (Completed) CZ (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2005-005537-35 Sponsor Protocol Number: E5564-G000-301 Start Date*: 2006-08-30
    Sponsor Name:Eisai Limited
    Full Title: ACCESS: A Controlled Comparison of Eritoran Tetrasodium and Placebo in Patients with Severe Sepsis
    Medical condition: Severe Sepsis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10040047 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) NL (Completed) AT (Completed) CZ (Completed) ES (Completed) DE (Completed) PT (Prematurely Ended) IT (Prematurely Ended) GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 37  38  39  40  41  42  43  44  45  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Apr 25 06:51:04 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA